THERAPY DOSSIER · th-7e4492ef8e6c

FPTIII; MG132; angiotensin-(1-7)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 8

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT01882374 ↗PHASE2withdrawn

Phase II TXA127 (Angiotensin 1-7) to Reduce Acute GvHD in Double Umbilical Cord Blood Transplantation

Hematologic Malignancies

Enrolment: 0 · Results not recorded

NCT03159988 ↗PHASE2suspended

Angiotensin (1-7) Treatment to Improve Cognitive Functioning in Heart Failure Patients

Chronic Heart Failure · Cognitive Impairment

Enrolment: 6 · Results not recorded

NCT04605887 ↗PHASE2unknown

Angiotensin 1-7 as Therapy for Pneumonia Caused by SARS-CoV-2

COVID-19

Enrolment: 120 · Results not recorded

NCT04570501 ↗PHASE1/PHASE2withdrawn

Safety and Efficacy of Angiotensin (1-7) for Treatment of COVID-19 in Hospitalised Patients

COVID-19

Enrolment: 0 · Results not recorded

NCT05301192 ↗EARLY_PHASE1recruiting

Angiotensin-(1-7) Cardiovascular Effects in Aging

Aging

Enrolment: 26 · Results not recorded

NCT03001271 ↗EARLY_PHASE1unknown

Acute Effect of Angiotensin-(1-7) on Blood Pressure and Heart Rate in Healthy and Hypertensive Subjects

Hypertension

Enrolment: 32 · Results not recorded

NCT00471562 ↗PHASE1completed

Phase I Trial of Angiotensin 1-7 for Advanced Solid Tumors

Advanced Solid Tumour

Enrolment: 18 · Results not recorded

NCT03604289 ↗EARLY_PHASE1terminated

Cardiovascular Effects of Angiotensin 1-7 in Obesity Hypertension

Obesity · Hypertension

Enrolment: 8 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 21510818 ↗2011Mixed findings

Inhibition of Ras-GTPase farnesylation and the ubiquitin-proteasome system or treatment with angiotensin-(1-7) attenuates spinal cord injury-induced cardiac dysfunction.

RatSpinal cord injuryContusionSprague-Dawleyex vivo perfusion before ischaemia6 or 12 months after SCI, acutely before cardiac ischaemia

Model: weight-drop contusive spinal cord injury (T13) with ex vivo cardiac ischaemia-reperfusion

FPTIII, MG132 or angiotensin-(1-7) improved cardiac recovery after ischaemia in SCI-6 but not SCI-12 animals.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…